The Big Picture of IBDAn Interactive Experience Highlighting Recent Clinical Advances
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF, et al. Lancet. 2018;390(10114):2779-2789.
Coskun M, et al. Pharmacol Res. 2013;76:1-8.
Kim DH, Cheon JH. Immune Netw. 2017;17(1):25-40.
De Vries LCS, et al. J Crohns Colitis. 2017;11(7):885-893.
Olivera P, et al. Expert Rev Clin Immunol. 2017;13(7):693-703.
Sandborn WJ, et al. N Engl J Med. 2017;377(5):496-497.
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Vermeire S, et al. Lancet. 2017;389(10066):266-275.
An Interactive Experience Highlighting Recent Clinical Advances
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Targeting Immune Dysregulation and Delivering Comprehensive Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Got it? Treat it!
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Debates & Discussions on the Evolving Role of JAK Inhibitors